Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Future Growth Projections For The Denosumab Market Size?

The market for denosumab has seen swift expansion within the last few years. Forecasts suggest it will escalate from a size of $3.27 billion in 2024 to $3.67 billion in 2025, yielding a compound annual growth rate (CAGR) of 12.1%. Factors such as breakthroughs in clinical trials and research, FDA approvals and regulatory achievements, increasing consciousness about bone health, and strategic collaborations coupled with marketing efforts have driven the substantial growth during the historic period.

Expectations are set for a swift expansion in the denosumab market over the coming years, with forecasts predicting its growth to reach “$5.48 billion by 2029”, representing a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this projected growth during the forecast period include the growing incidence of bone metastases, advancements in cancer treatments, the prevalence of osteoporosis, heightened public awareness of osteoporosis, and regulatory approvals for new indications. Other key trends during the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications, and clinical applications, along with advancements in biosimilar development.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

What Drivers Are Accelerating Expansion Of The Denosumab Market?

The growth of the denosumab market is projected to be catalyzed by the rising incidence of osteoporosis. Osteoporosis is a medical condition characterized by weakening of bones, which leads to decreased bone density and increased risk of fractures. Denosumab plays a crucial role in osteoporosis treatment as it prevents bone resorption by targeting the RANK ligand. For example, the National Center for Biotechnology Information, a government agency from the USA, reported in September 2023 through data from the Canadian Longitudinal Study on Aging that the prevalence of osteoporosis diagnosed by physicians was 12.7% and DXA-confirmed osteoporosis was 5.9% among older adults living in community settings. Also, a cross-sectional study conducted by Buttros and colleagues showed an osteoporosis prevalence rate of 24.6% in postmenopausal women aged between 40 to 75, determined using bone mineral density (BMD) tests. Thus, with the rise in osteoporosis prevalence, the denosumab market is experiencing significant growth.

What Segmentation Insights Are Provided In The Denosumab Market Research?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Which Notable Trends Are Transforming The Denosumab Market Outlook?

Leading companies within the denosumab market are intensifying their efforts to launch innovative solutions, such as primary treatments for osteoporosis, to secure an advantageous position in the marketplace. The term first-line treatment for osteoporosis denotes the initial or most preferred treatment strategy offered by healthcare professionals to individuals diagnosed with osteoporosis. For instance, in November 2022, approval was granted to Boan Biotech, a biotechnology company based in China, by China’s National Medical Products Administration (NMPA) for Boyoubei, its denosumab biosimilar. This achievement established Boan Biotech as the first Chinese company to create a denosumab injection. The firm is also developing for international markets beyond China, incorporating Europe and the United States, with plans for a global marketing strategy. This drug has been proposed as a primary treatment for osteoporosis in several treatment guidelines. It harbours the potential to greatly reduce the risk of hip, non-vertebral, and vertebral fractures in patients with osteoporosis. Moreover, Boyoubei is the world’s first biosimilar to Prolia, the original creator of denosumab, to be approved for marketing.

Who Are The Major Stakeholders Operating In The Denosumab Market?

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Denosumab Market?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model